Dopaminergic dysregulation in schizophrenia: A target for new drugs

Kenneth L. Davis*, Michael Fiori, Bonnie M. Davis, Richard C. Mohs, Thomas B. Horvath, Michael Davidson

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

6 Scopus citations


The dopamine hypothesis postulates that at least some schizophrenic symptoms are a reflection of central nervous system hyperdopaminergia. The evidence for this model is briefly reviewed and its shortcomings highlighted. The dysregulation hypothesis of schizophrenia should be a useful reformulation. Rather than conceptualizing a static hyperdopaminergic state, schizophrenia might be better understood as a reflection of a relative failure of dopaminergic regulation. Evidence for such dysregulation is examined and possible mechanisms are presented. Avenues of future drug research are proposed.

Original languageEnglish
Pages (from-to)71-83
Number of pages13
JournalDrug Development Research
Issue number1
StatePublished - Sep 1986
Externally publishedYes


  • DA — dopamine
  • GH — growth hormone
  • PGE — prostaglandin E
  • pHVA — plasma homovanillic acid


Dive into the research topics of 'Dopaminergic dysregulation in schizophrenia: A target for new drugs'. Together they form a unique fingerprint.

Cite this